<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Level of Health - Medical Blog &#187; Diabetes</title>
	<atom:link href="http://www.levelofhealth.com/category/diabetes/feed" rel="self" type="application/rss+xml" />
	<link>http://www.levelofhealth.com</link>
	<description></description>
	<lastBuildDate>Mon, 12 Jul 2010 11:17:05 +0000</lastBuildDate>
	<generator>http://wordpress.org/?v=2.8.4</generator>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
			<item>
		<title>Pfizer Diabetes</title>
		<link>http://www.levelofhealth.com/diabetes/pfizer-diabetes.html</link>
		<comments>http://www.levelofhealth.com/diabetes/pfizer-diabetes.html#comments</comments>
		<pubDate>Tue, 18 May 2010 12:48:23 +0000</pubDate>
		<dc:creator>Ben Judd</dc:creator>
				<category><![CDATA[Diabetes]]></category>
		<category><![CDATA[Pfizer Diabetes]]></category>

		<guid isPermaLink="false">http://www.levelofhealth.com/?p=1161</guid>
		<description><![CDATA[Occasionally, in this space, we review matters of concern to consumers and clinicians regarding clinical care. Recently, I commented on 1 on 1 health™, the consumer Web portal for GlaxoSmithKline (P&#38;T February 2004). In this issue of P&#38;T, I would like to add some context for another important Web portal for consumers and physicians, namely.
I [...]]]></description>
		<wfw:commentRss>http://www.levelofhealth.com/diabetes/pfizer-diabetes.html/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Statins and Diabetes Mellitus: part 2</title>
		<link>http://www.levelofhealth.com/diabetes/statins-and-diabetes-mellitus-part-2.html</link>
		<comments>http://www.levelofhealth.com/diabetes/statins-and-diabetes-mellitus-part-2.html#comments</comments>
		<pubDate>Wed, 31 Mar 2010 11:57:40 +0000</pubDate>
		<dc:creator>Ben Judd</dc:creator>
				<category><![CDATA[Diabetes]]></category>
		<category><![CDATA[diabetes mellitus]]></category>
		<category><![CDATA[statins]]></category>

		<guid isPermaLink="false">http://www.levelofhealth.com/?p=1002</guid>
		<description><![CDATA[HDL also seems to be more quickly hydrolyzed in patients with insulin resistance, leading to lower HDL levels. Statins can reduce LDL levels by 18% to 55% and triglycerides by 7% to 30%; they can also increase HDL levels by 5% to 15%.
Although few studies have been directed solely toward statin use in the diabetic [...]]]></description>
		<wfw:commentRss>http://www.levelofhealth.com/diabetes/statins-and-diabetes-mellitus-part-2.html/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Statins and Diabetes Mellitus</title>
		<link>http://www.levelofhealth.com/diabetes/statins-and-diabetes-mellitus.html</link>
		<comments>http://www.levelofhealth.com/diabetes/statins-and-diabetes-mellitus.html#comments</comments>
		<pubDate>Tue, 30 Mar 2010 12:12:38 +0000</pubDate>
		<dc:creator>Ben Judd</dc:creator>
				<category><![CDATA[Diabetes]]></category>
		<category><![CDATA[diabetes mellitus]]></category>
		<category><![CDATA[statins]]></category>

		<guid isPermaLink="false">http://www.levelofhealth.com/?p=1001</guid>
		<description><![CDATA[The number of people living with diabetes mellitus in the U.S. has crossed the 20 million mark, with 1.5 million cases having been diagnosed in 2005 alone. Because nearly 65% of this population will suffer from heart disease or stroke, it is crucial for health care professionals to continually investigate the efficacy of current diabetes [...]]]></description>
		<wfw:commentRss>http://www.levelofhealth.com/diabetes/statins-and-diabetes-mellitus.html/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Rimonabant (Acomplia): DOSAGE</title>
		<link>http://www.levelofhealth.com/diabetes/rimonabant-acomplia-dosage.html</link>
		<comments>http://www.levelofhealth.com/diabetes/rimonabant-acomplia-dosage.html#comments</comments>
		<pubDate>Mon, 15 Mar 2010 14:12:37 +0000</pubDate>
		<dc:creator>Ben Judd</dc:creator>
				<category><![CDATA[Diabetes]]></category>
		<category><![CDATA[Cancer]]></category>
		<category><![CDATA[Rimonabant]]></category>

		<guid isPermaLink="false">http://www.levelofhealth.com/?p=925</guid>
		<description><![CDATA[
It is expected that the usual dose of canadian rimonabant will be 20 mg once daily before breakfast. No dosage adjustment is recommended for the elderly, but this agent should be used with caution in patients older than 75 years of age.
Although rimonabant can be used in patients with mild hepatic impairment, caution is advised [...]]]></description>
		<wfw:commentRss>http://www.levelofhealth.com/diabetes/rimonabant-acomplia-dosage.html/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Rimonabant (Acomplia): EFFICACY IN CLINICAL TRIALS</title>
		<link>http://www.levelofhealth.com/diabetes/rimonabant-acomplia-efficacy-in-clinical-trials.html</link>
		<comments>http://www.levelofhealth.com/diabetes/rimonabant-acomplia-efficacy-in-clinical-trials.html#comments</comments>
		<pubDate>Sun, 14 Mar 2010 14:12:36 +0000</pubDate>
		<dc:creator>Ben Judd</dc:creator>
				<category><![CDATA[Diabetes]]></category>
		<category><![CDATA[Cancer]]></category>
		<category><![CDATA[Rimonabant]]></category>

		<guid isPermaLink="false">http://www.levelofhealth.com/?p=924</guid>
		<description><![CDATA[
Four published clinical trials have assessed the efficacy and safety of rimonabant in the treatment of obesity and cardiometabolic risk factors. Other studies of the drug have been presented as posters at clinical meetings, but they are not reviewed in this article.
The iSmonabant In Obesity (RIO) Program consists of four published clinical trials comparing rimonabant [...]]]></description>
		<wfw:commentRss>http://www.levelofhealth.com/diabetes/rimonabant-acomplia-efficacy-in-clinical-trials.html/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Rimonabant (Acomplia): CHEMICAL AND PHYSICAL PROPERTIES/MECHANISM OF ACTION</title>
		<link>http://www.levelofhealth.com/diabetes/rimonabant-acomplia-chemical-and-physical-propertiesmechanism-of-action.html</link>
		<comments>http://www.levelofhealth.com/diabetes/rimonabant-acomplia-chemical-and-physical-propertiesmechanism-of-action.html#comments</comments>
		<pubDate>Sat, 13 Mar 2010 14:12:35 +0000</pubDate>
		<dc:creator>Ben Judd</dc:creator>
				<category><![CDATA[Diabetes]]></category>
		<category><![CDATA[Cancer]]></category>
		<category><![CDATA[Rimonabant]]></category>

		<guid isPermaLink="false">http://www.levelofhealth.com/?p=923</guid>
		<description><![CDATA[
Rimonabant [,/V-piperino-5-(4-chloro-phenyl)-1-1(2,4-dichlorophenyl)-4-meth-ylpyrazole-3-carvoxamide] is a CB1 antagonist. At low concentrations, it may also act as an inverse agonist.8 At very high concentrations, canadian rimonabant also behaves as a CB2 receptor antagonist, blocks calcium and potassium channels, and may directly affect cellular gap junctions.
Cannabinoid receptors are members of the G-protein coupled receptor (GPCR) superfamily of cell-surface heptahelical [...]]]></description>
		<wfw:commentRss>http://www.levelofhealth.com/diabetes/rimonabant-acomplia-chemical-and-physical-propertiesmechanism-of-action.html/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Rimonabant (Acomplia)</title>
		<link>http://www.levelofhealth.com/diabetes/rimonabant-acomplia.html</link>
		<comments>http://www.levelofhealth.com/diabetes/rimonabant-acomplia.html#comments</comments>
		<pubDate>Fri, 12 Mar 2010 14:12:33 +0000</pubDate>
		<dc:creator>Ben Judd</dc:creator>
				<category><![CDATA[Diabetes]]></category>
		<category><![CDATA[Cancer]]></category>
		<category><![CDATA[Rimonabant]]></category>

		<guid isPermaLink="false">http://www.levelofhealth.com/?p=922</guid>
		<description><![CDATA[
INTRODUCTION
The prevalence of obesity continues to rise. Current data indicate that the combined prevalence of overweight and obesity in adults in the U.S. is 66.3%. The prevalence for obesity alone in adults is 32.2%; for extreme obesity in adults, this figure is 4.8%. Approximately 17.1% of children and adolescents in the U.S. are overweight. Overweight [...]]]></description>
		<wfw:commentRss>http://www.levelofhealth.com/diabetes/rimonabant-acomplia.html/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
